Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment

• Published in: Drug design, development and therapy development and therapy, 2021-01, Vol.15, p.3475-3486
• Main Authors: Mao, Kaiping, Zhang, Weina, Yu, Lan, Yu, Yi, Liu, Haixia, Zhang, Xiaotao
• Format: Article
• Language: English
• Subjects: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis; B cells; Biocompatibility; Cancer; Cancer therapies; Carboplatin; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Care and treatment; Cell Line, Tumor; Chemotherapy; Cisplatin; Cisplatin - administration & dosage; Cytotoxicity; Docetaxel; Docetaxel - administration & dosage; Drug Delivery Systems; Drug resistance; Drug Synergism; Drug therapy; Drugs; Health aspects; Humans; hybrid nanoparticles; In vivo methods and tests; Lipids; Liposomes; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; nanostructured lipid nanoparticles; Non-small cell lung carcinoma; Original Research; Particle Size; protein nanoparticles; Proteins; Respiratory agents; Small cell lung carcinoma; Synergistic effect; Toxicity; Transferrin; Transferrin - chemistry; Transferrins; Xenograft Model Antitumor Assays
• ISSN: 1177-8881; 1177-8881
• DOI: 10.2147/DDDT.S296253

Non-small cell lung cancer (NSCLC) therapy faces the barriers including drug resistance. A transferrin-functionalized protein-lipid hybrid nanoparticle (PLHN) was designed loading both cisplatin (CIS) and docetaxel (DTX) for the lung cancer treatment. CIS and DTX were loaded into the hybrid nanoparticle and then decorated with transferrin (Tf). The Tf-functionalized protein-lipid hybrid nanoparticle (Tf-CIS/DTX-PLHN) was investigated by determining the release behavior, cytotoxicity in vitro, and anticancer efficiency in vivo. Tf-CIS/DTX-PLHN showed a nano-size of 189.5 ± 5.9 nm, and a surface tested to be -16.9 ± 2.1 mV. Tf-CIS/DTX-PLHN exhibited obviously better antitumor ability in vitro and in vivo compared with the non Tf contained CIS and DTX co-loaded lipid nanoparticles (CIS/DTX-LN), single drug loaded nanoparticles, and free drugs. Since remarkable enhanced efficiency of Tf and synergistic effect of the drugs, it could inhibit the lung tumor growth and help with the lung cancer treatment.